Akoya Biosciences, Inc. Company Profile

Background

Akoya Biosciences, Inc., known as "The Spatial Biology Company®," specializes in providing comprehensive solutions for spatial phenotyping. Their mission is to bring context to biology and human health by enabling researchers to visualize and understand cellular organization and interactions within tissue samples. This approach is pivotal in advancing research areas such as oncology, immunotherapy, and neuroscience.

Key Strategic Focus

Akoya's strategic focus centers on delivering end-to-end spatial biology solutions that cater to the diverse needs of researchers across discovery, translational, and clinical research. Their product portfolio includes:

• PhenoCycler®-Fusion: An ultrahigh-plex platform for spatial discovery, capable of profiling over 100 analytes in a single experiment.

• PhenoImager® HT: A high-throughput platform designed for translational and clinical applications.

These platforms are complemented by PhenoCode™ Panels, which facilitate multiplex immunofluorescence technologies measuring 6-8 biomarkers. Akoya's solutions are integral to global initiatives like the Human Tumor Atlas Network (HTAN) and the Human BioMolecular Atlas Program (HuBMAP), underscoring their commitment to advancing spatial biology research.

Financials and Funding

In the fiscal year ending December 31, 2024, Akoya reported:

• Total Revenue: $81.7 million, a 15.5% decrease from the previous year.

• Gross Margin: 58.6%, with a non-GAAP adjusted gross margin of 61.1% after excluding write-offs from discontinued legacy products.

• Operating Expenses: $94.6 million, reduced to $88.6 million on a non-GAAP basis, excluding impairment and restructuring charges.

• Loss from Operations: $46.7 million, with a non-GAAP loss of $38.6 million.

As of December 31, 2024, the company had an instrument installed base of 1,330 units and 1,733 total publications citing its technology, reflecting a 12.4% and 49.4% increase, respectively, from the prior year.

Technological Platform and Innovation

Akoya's technological platforms are distinguished by their proprietary technologies and scientific methodologies:

• PhenoCycler®-Fusion: Enables ultrahigh-plex spatial discovery, allowing researchers to profile over 100 analytes simultaneously.

• PhenoImager® HT: Designed for high-throughput translational and clinical applications, facilitating efficient analysis of tissue samples.

These platforms utilize advanced multiplex immunofluorescence and spatial proteomics techniques, providing unparalleled insights into tissue biology. Notably, Nature Methods recognized spatial proteomics as the "Method of the Year 2024," highlighting its transformative impact on biological research and medicine.

Leadership Team

Akoya's leadership team comprises experienced professionals dedicated to advancing spatial biology:

• Brian McKelligon: Chief Executive Officer

• Scott Mendel: Chairman of the Board of Directors (appointed October 2, 2024)

Mr. Mendel brings over 30 years of financial and operational management experience to the board.

Competitor Profile

Market Insights and Dynamics

The spatial biology market is experiencing significant growth, driven by advancements in technologies that enable detailed mapping of cellular environments. This growth is fueled by increasing applications in oncology, immunotherapy, and neuroscience research.

Competitor Analysis

Key competitors in the spatial biology sector include:

• NanoString Technologies: Offers the GeoMx Digital Spatial Profiler, enabling high-plex spatial analysis of tissue samples.

• 10x Genomics: Provides the Visium Spatial Gene Expression platform, integrating spatial and gene expression analysis.

These companies, along with Akoya, are at the forefront of developing technologies that enhance the understanding of tissue architecture and cellular interactions.

Strategic Collaborations and Partnerships

Akoya has engaged in significant collaborations to strengthen its market position:

• NeraCare Partnership: In December 2024, Akoya entered into an exclusive global license agreement with NeraCare to develop and commercialize the Immunoprint test on Akoya's multiplexed immunofluorescent platform. This test aims to identify early-stage melanoma patients at high risk of relapse, potentially guiding treatment decisions and expanding access to life-saving therapies.

• MANIFEST Program: Akoya's spatial proteomics platforms, PhenoCycler-Fusion and PhenoImager HT, were selected for the UK-wide MANIFEST program. This multi-million-dollar initiative, led by the Francis Crick Institute and the Royal Marsden NHS Foundation Trust, focuses on evaluating thousands of patient samples to better understand responses to cancer immunotherapy.

Operational Insights

Akoya's strategic initiatives, including the expansion of its product portfolio and strategic partnerships, position the company to address the growing demand for spatial biology solutions. The company's focus on innovation and collaboration enhances its competitive advantage in the rapidly evolving spatial biology market.

Strategic Opportunities and Future Directions

Looking ahead, Akoya aims to:

• Expand Clinical Applications: Leverage partnerships like the one with NeraCare to develop diagnostic tests that can be integrated into clinical workflows.

• Enhance Technological Capabilities: Continue advancing their platforms to offer higher plex capabilities and improved throughput, meeting the evolving needs of researchers.